BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11004427)

  • 1. Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels.
    Ashcroft FM; Gribble FM
    J Diabetes Complications; 2000; 14(4):192-6. PubMed ID: 11004427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues.
    Gribble FM; Ashcroft FM
    Metabolism; 2000 Oct; 49(10 Suppl 2):3-6. PubMed ID: 11078468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions.
    Gribble FM; Reimann F
    J Diabetes Complications; 2003; 17(2 Suppl):11-5. PubMed ID: 12623163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels.
    Gribble FM; Tucker SJ; Seino S; Ashcroft FM
    Diabetes; 1998 Sep; 47(9):1412-8. PubMed ID: 9726229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential sensitivity of beta-cell and extrapancreatic K(ATP) channels to gliclazide.
    Gribble FM; Ashcroft FM
    Diabetologia; 1999 Jul; 42(7):845-8. PubMed ID: 10440127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular mechanisms of insulin secretion].
    Bataille D
    Diabetes Metab; 2002 Dec; 28(6 Suppl):4S7-13. PubMed ID: 12703060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulfonylurea stimulation of insulin secretion.
    Proks P; Reimann F; Green N; Gribble F; Ashcroft F
    Diabetes; 2002 Dec; 51 Suppl 3():S368-76. PubMed ID: 12475777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.
    Sunaga Y; Gonoi T; Shibasaki T; Ichikawa K; Kusama H; Yano H; Seino S
    Eur J Pharmacol; 2001 Nov; 431(1):119-25. PubMed ID: 11716850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic and extrapancreatic sulfonylurea receptors.
    Panten U; Schwanstecher M; Schwanstecher C
    Horm Metab Res; 1992 Dec; 24(12):549-54. PubMed ID: 1478610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stoichiometry of sulfonylurea-induced ATP-sensitive potassium channel closure.
    Dörschner H; Brekardin E; Uhde I; Schwanstecher C; Schwanstecher M
    Mol Pharmacol; 1999 Jun; 55(6):1060-6. PubMed ID: 10347249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets.
    Panten U; Burgfeld J; Goerke F; Rennicke M; Schwanstecher M; Wallasch A; Zünkler BJ; Lenzen S
    Biochem Pharmacol; 1989 Apr; 38(8):1217-29. PubMed ID: 2650685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucose regulation of insulin secretion independent of the opening or closure of adenosine triphosphate-sensitive K+ channels in beta cells.
    Sato Y; Anello M; Henquin JC
    Endocrinology; 1999 May; 140(5):2252-7. PubMed ID: 10218978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for the interference between nicorandil and sulfonylurea action.
    Reimann F; Ashcroft FM; Gribble FM
    Diabetes; 2001 Oct; 50(10):2253-9. PubMed ID: 11574406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels.
    Song DK; Ashcroft FM
    Br J Pharmacol; 2001 May; 133(1):193-9. PubMed ID: 11325810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
    Hu S; Wang S; Fanelli B; Bell PA; Dunning BE; Geisse S; Schmitz R; Boettcher BR
    J Pharmacol Exp Ther; 2000 May; 293(2):444-52. PubMed ID: 10773014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulfonylurea and non-sulfonylurea hypoglycemic agents: pharmachological properties and tissue selectivity.
    Nagashima K; Takahashi A; Ikeda H; Hamasaki A; Kuwamura N; Yamada Y; Seino Y
    Diabetes Res Clin Pract; 2004 Dec; 66 Suppl 1():S75-8. PubMed ID: 15563985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels.
    Kramer W; Müller G; Girbig F; Gutjahr U; Kowalewski S; Hartz D; Summ HD
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S67-80. PubMed ID: 8529521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sulfonylureas on K(ATP) channel-dependent vasodilation.
    Cyrino FZ; Bottino DA; Coelho FC; Ravel D; Bouskela E
    J Diabetes Complications; 2003; 17(2 Suppl):6-10. PubMed ID: 12623162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulfonylureas enhance exocytosis from pancreatic beta-cells by a mechanism that does not involve direct activation of protein kinase C.
    Tian YA; Johnson G; Ashcroft SJ
    Diabetes; 1998 Nov; 47(11):1722-6. PubMed ID: 9792541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidiabetic sulfonylurea stimulates insulin secretion independently of plasma membrane KATP channels.
    Geng X; Li L; Bottino R; Balamurugan AN; Bertera S; Densmore E; Su A; Chang Y; Trucco M; Drain P
    Am J Physiol Endocrinol Metab; 2007 Jul; 293(1):E293-301. PubMed ID: 17405830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.